RxDoctor Payments Data

Ajay Patel, MD

Interventional Cardiology · Bakersfield, CANPI 1205114899

Payments from drug & device makers

$145,003in general payments, 2019–2025

Across 788 payments — averaging $184.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$80K
  • Medtronic$14K
  • Shockwave Medical, Inc$12K
  • Bayer$10K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
  • Abbott$6K
  • plus $16K from 35 others

What the payments were for

  • Consulting fees$4,5003%
  • Speaking & faculty fees$81,75856%
  • Travel & lodging$27,50119%
  • Food & beverage$31,24422%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$145,003 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$585,368
Medicare patients
1,476
Services billed
4,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban290$343,437
FarxigaDapagliflozin Propanediol166$147,964
Repatha SureclickEvolocumab161$131,812
EntrestoSacubitril/Valsartan72$93,595
JardianceEmpagliflozin70$74,610
XareltoRivaroxaban52$57,024
Praluent PenAlirocumab48$43,159
KerendiaFinerenone30$20,995
OzempicSemaglutide20$20,764
NexlizetBempedoic Acid/Ezetimibe23$19,186
BrilintaTicagrelor19$16,379
VascepaIcosapent Ethyl23$15,326
Icosapent Ethyl35$13,477
Atorvastatin Calcium962$10,318
ClopidogrelClopidogrel Bisulfate429$4,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$343,437290 claims
AstraZenecaFarxiga, Brilinta$101$164,344185 claims
NovartisEntresto$675$93,59572 claims
Boehringer IngelheimJardiance$185$74,61070 claims
BayerKerendia$10,246$20,99530 claims
Novo NordiskOzempic$40$20,76420 claims
Esperion Therapeutics, Inc.Nexlizet$65$19,18623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →